LiverMultiScan Analysis of MRI Scans in HCC

NCT04451603 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2024-03-13

No results posted yet for this study

Summary

This project is a pilot study to interrogate the potential of LMS as a predictive tool for the selection of therapy for HCC patients. The reliability of LMS to predict patients' response following HCC therapy will leverage on an algorithm that is built from the pool of MRI scans from HCC patients pre- and post-treatment. In the study, MRI scans of 30 HCC and metastatic colorectal cancer (CM) patients (ratio of 4:1) will be analysed. CM cancer patients include patients whose cancers metastasized from colorectal cancer or primary liver cancer. These patients will either receive one of the treatment, surgical resection, Y90 or systemic therapy. A total of 4 MRI scans will be taken for each patient; the first MRI scan will be taken within a month before treatment initiation and the remaining MRI scans will be taken at the 1st, 3rd and 9th month post-initiation of treatment.

Conditions

Interventions

PROCEDURE

Surgery

Surgical resection of the liver

RADIATION

Radiation therapy

Y-90 radioembolization therapy is the main treatment

DRUG

Drug treatment

Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors

Sponsors & Collaborators

  • Perspectum

    collaborator INDUSTRY
  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Pierce Chow · National Cancer Centre, Singapore

Eligibility

Min Age
21 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-19
Primary Completion
2021-03-16
Completion
2023-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04451603 on ClinicalTrials.gov